BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1125 related articles for article (PubMed ID: 21937200)

  • 21. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
    Magro CM; Dyrsen ME
    J Cutan Pathol; 2008 Nov; 35(11):1040-9. PubMed ID: 18681860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.
    Gjerdrum LM; Woetmann A; Odum N; Burton CM; Rossen K; Skovgaard GL; Ryder LP; Ralfkiaer E
    Leukemia; 2007 Dec; 21(12):2512-8. PubMed ID: 17713545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma.
    Funk A; Hensley F; Krempien R; Neuhof D; Van Kampen M; Treiber M; Roeder F; Timke C; Herfarth K; Helmbold P; Debus J; Bischof M
    Eur J Dermatol; 2008; 18(3):308-12. PubMed ID: 18474461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
    Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R
    Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The spectrum of cutaneous lymphomas in patients less than 20 years of age.
    Fink-Puches R; Chott A; Ardigó M; Simonitsch I; Ferrara G; Kerl H; Cerroni L
    Pediatr Dermatol; 2004; 21(5):525-33. PubMed ID: 15461755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
    Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
    J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group.
    Senff NJ; Willemze R
    Br J Dermatol; 2007 Dec; 157(6):1205-11. PubMed ID: 17941944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome.
    Woo DK; Jones CR; Vanoli-Storz MN; Kohler S; Reddy S; Advani R; Hoppe RT; Kim YH
    Arch Dermatol; 2009 Jun; 145(6):667-74. PubMed ID: 19528422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TOX expression in different subtypes of cutaneous lymphoma.
    Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
    Benner MF; Jansen PM; Meijer CJ; Willemze R
    Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.
    Quaglino P; Pimpinelli N; Berti E; Calzavara-Pinton P; Alfonso Lombardo G; Rupoli S; Alaibac M; Bottoni U; Carbone A; Fava P; Fimiani M; Mamusa AM; Titli S; Zinzani PL; Bernengo MG;
    Cancer; 2012 Dec; 118(23):5830-9. PubMed ID: 22674564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients.
    Kunishige JH; McDonald H; Alvarez G; Johnson M; Prieto V; Duvic M
    Clin Exp Dermatol; 2009 Jul; 34(5):576-81. PubMed ID: 19196298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases.
    Saggini A; Gulia A; Argenyi Z; Fink-Puches R; Lissia A; Magaña M; Requena L; Simonitsch I; Cerroni L
    Am J Surg Pathol; 2010 Aug; 34(8):1168-75. PubMed ID: 20661014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
    Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
    Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
    J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases.
    Coupland SE; Foss HD; Assaf C; Auw-Haedrich C; Anastassiou G; Anagnostopoulos I; Hummel M; Karesh JW; Lee WR; Stein H
    Ophthalmology; 1999 Nov; 106(11):2109-20. PubMed ID: 10571346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.